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Abstract
Background: Erosive degenerative disc disease, also known as Modic type 1 changes, is usually characterized by
low back pain with an inflammatory pain pattern, as seen in spondyloarthropathies. Intravenous pamidronate has
proven to be effective in patients with ankylosing spondylitis who are refractory to nonsteroidal antiinflammatory
drugs, and in painful bone diseases in general, such as Paget’s disease, fibrous dysplasia or vertebral fractures. We
therefore hypothesize that pamidronate would be effective in treating low back pain associated with Modic type 1
changes.
Methods/Design: This study, called PEPTIDE (short for the French title “Etude Prospective sur l’Efficacité et la
tolérance du PamidronaTe dans les dIscopathies Degeneratives Erosives”), will be a double-blind, randomized,
placebo-controlled, parallel group, phase two clinical trial. A total of 48 patients will be recruited. These patients will
be randomly assigned to one of the two groups, with 24 patients in each group: one group will be given pamidronate
and the other a placebo. Pamidronate will be administered at a dose of 90 mg per day for two days consecutively, and
every patient, irrespective of treatment group, will be given paracetamol to maintain blinding by preventing drug-
induced fever. The primary outcome measure is a between-group difference of 30 points on a 100 mm Visual
Analogue Scale (VAS) at three months. Secondary outcome measures are improvement in functional status and the
drug’s safety. Primary and secondary outcome measures will be assessed at each visit (inclusion, at six weeks, three
months, and six months). If the primary goal is not attained, the patient will be offered a rigid or semi-rigid back brace,
irrespective of the treatment group.
Discussion: To date, only local treatments, for example intradiscal corticosteroid therapy, lumbar arthrodesis or back
braces have been studied in randomized, controlled trials, with controversial results. This trial is currently ongoing and,
if conclusive, should provide physicians with an acceptable alternative to those treatments. The results should be
publicly available in spring 2015.
Trial registration: ClinicalTrials.gov number, NCT01799616.
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Background
In 1988, Modic et al. suggested a classification scheme
for endplate changes associated with erosive degenera-
tive disk disease (EDDD) at the lumbar spine. Type 1 is
characterized on a magnetic resonance imaging (MRI)
scan by low signal on T1 and increased signal on T2 im-
ages, indicating bony edema [1]. EDDD is mostly a
French denomination for a type of non-infectious ero-
sive disease of the spine, among others, such as crystal
deposition disease, erosive discopathy in patients under
chronic hemodialyses and rheumatic diseases with in-
flammatory discopathy. EDDD is the degenerative, or
osteoarthritic, subcategory of noninfectious erosive disk
diseases. Erosions are not an essential feature of Modic
type 1 changes, but the two have often been associated,
since studies have described a constant presence of
Modic type 1 changes in EDDD [2]. Moreover, usually
superficial erosions have been described as one of the
elementary bone lesions in degenerative disk disease as-
sociated with Modic type 1 changes [3]. Since ‘Modic
type 1 changes’ is supposedly a radiological definition
and does not encompass the clinical aspect, it has been
accepted for a long time, in France at least, that we
speak of EDDD, recently changed to ‘active discopathy’.
The correlation between Modic type 1 changes and
back pain is still a matter of debate. There is however, to
this date, far more evidence in favor of a real relation-
ship between the two than otherwise. A 2008 systematic
review [4] thus found ‘a positive association between
vertebral endplate signal changes (VESC, or Modic
changes), and low back pain (LBP) in the majority of
studies reporting on this subject’, with Odds Ratios in
the studies that reported a statistically significant posi-
tive association ranged between 2.0 and 19.9. Moreover,
‘a positive association between VESC and LBP has not
only been found in the majority of studies of patients
with LBP from different countries, but also in the gen-
eral and working populations. In other words, there is a
considerable consistency in this association’ [4].
Another 2008 review [5] confirmed the possibility of
asymptomatic individuals with Modic changes but em-
phasized on its infrequency [6-8], and concluded that
type 1 changes are ‘likely to be inflammatory in origin
and seem to be strongly associated with active low back
symptoms and segmental instability, thus reflecting a
state of active degeneration and biomechanical instability
of the lumbar spine’. For an MRI classification, Modic
changes are therefore usually considered a validated clin-
ical finding; Toyone et al. observed that 73% of patients
with type 1 changes had low back pain, making asymp-
tomatic subjects much less common than those with
type 2 changes (11%) [6]. Modic type 1 changes have
also been found to be specifically associated with the
presence of low back pain [9], supporting the hypothesis
that this early stage of the Modic disease is active [10].
Moreover, patients with Modic type 1 changes usually
experience acute flares of previous common chronic
lower back pain, usually with an inflammatory pattern
[11]. Therefore, the clinical presentation of EDDDs
mimics that of spondyloarthropathies (SpA), with conse-
quent first-line treatment based on the use of nonsteroi-
dal antiinflammatory drugs (NSAIDs) [12]. However,
these treatments can be inadequate or even totally inef-
fective (at least 25% of patients are said to be refractory
to NSAIDs), and sometimes poorly tolerated (gastroduo-
denal ulcers, arterial hypertension, and so forth) [13].
Corticosteroid therapy, which is not indicated for com-
mon low back pain, has been suggested for EDDDs by
Maigne and Ballard, but over 50% of patients in the only
open-label study experienced therapeutic failure [14].
Local treatments have been suggested, ranging from
intradiscal cortisone injections to arthrodesis [15-20].
The results are, however, controversial [21,22]. These in-
vasive procedures expose the patient to a risk of infection
for intradiscal injections and to operating complications
for arthrodesis [19].
Pamidronate, intravenous bisphosphonate with action
on bone turnover, has shown some efficacy in open-label
studies on spondyloarthropathies that are resistant to
NSAIDs, whether on ankylosing spondylitis or SAPHO
(Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) syn-
drome [22-31]. Although this efficacy in spondyloarthro-
pathies remains a topic of discussion, it has nevertheless
been clearly demonstrated for various types of bone pain
(Paget’s disease [32], fibrous dysplasia of bone [33] and
vertebral compression [34,35]). Therefore, we conducted
an open-label study on the efficacy of pamidronate in
ten patients with EDDD in 2006, with conclusive results
[36]. At one year, four patients deemed their overall im-
provement to be excellent (85 to 100%), four to be good
(70 to 85%) and two to be poor (< 55%). The inflamma-
tory pain pattern disappeared as early as the first month
in four patients and after one year in nine out of ten pa-
tients. Mean scores on the Visual Analogue Scale (VAS)
showed gradual improvement, which was significant at
six months (35.1 ± 30.2 mm; p = 0.05) and one year
(32.1 ± 24 mm; p = 0.01). The improvement was quickly
significant on the Quebec scale (a 20-item self-
administered instrument designed to assess the level of
functional disability in individuals with back pain), at
one month (26 ± 27.7; p = 0.02) and at one year (15.8 ±
18; p = 0.001). The mean Schober score, measuring lum-
bar flexion mobility, was unchanged.
The objective of this clinical trial is to demonstrate the
efficacy of pamidronate in degenerative disc diseases by
conducting a prospective, randomized, placebo-controlled
study. Patients with inflammatory low back pain and a
Modic type 1 change on their MRI, whose inclusion and
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exclusion criteria are detailed in Table 1, will be randomly
assigned to one of two groups: one group will be given
pamidronate and the other placebo. Pamidronate will be
administered at a dose of 90 mg per day for two days con-
secutively. The primary outcome measure is a between-
group difference of 30 points on a 100 mm VAS at three
months. Secondary outcome measures are improvement
in functional status and the drug’s safety. In case of failure
at three months, it will be recommended that the patient,
irrespective of the treatment initially received, wear a rigid
or semi-rigid dorsolumbar brace, whose efficacy will be
evaluated using the same criteria at six months to ensure
the patient is at least partially relieved at the end of the
study, provided that they had not used a brace before the
start of the study.
Methods and design
Study design and location
PEPTIDE will be a double-blind, randomized, placebo-
controlled on a 1:1 ratio, parallel group, phase two clin-
ical trial. The endpoints will be measured at baseline, six
weeks, three months and six months. In case of failure
to alleviate pain with pamidronate at three months, a
rigid back brace will be offered to all patients irrespect-
ive of the treatment group, and its efficacy will be
assessed at six months. PEPTIDE will be conducted in
the Rheumatology Department of Clermont-Ferrand
University Hospital in France.
To maintain blinding, every patient regardless of the
group they are in, will be given paracetamol to prevent
pamidronate-induced fever insofar as is possible, and the
product will only be labelled with the patient ran-
domization number. Moreover, both the nurses and phy-
sicians from the rheumatology department responsible
for administering the product and looking for side ef-
fects will be blinded to the participants’ status, and the
assessments will be performed by physicians from the
Physical Medicine and Rehabilitation Department who
are unaware of said side effects.
Participants
Participants are currently being recruited for this study
from the Rheumatology and Physical Medicine and Re-
habilitation Departments of Clermont-Ferrand University
Hospital, and from the patients of local rheumatologists in
private practice. The inclusion and exclusion criteria are
described in Table 1.
Approval
All patients will provide their informed consent and the
study will be conducted according to the principles of
the Declaration of Helsinki. This protocol has been ap-
proved by the Sud-Est VI Ethics Committee, which is af-
filiated with Clermont-Ferrand University Hospital, and
by the French National Agency for Medicines and
Health Products Safety (ANSM).
Randomization
The randomization list will be drawn up by the method-
ologist in charge of the project before the start of the
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
- Aged between 18 and 60 years - Static disorders of the spine
- Low back pain with an inflammatory pattern (at least one of three
characteristics: waking at night due to pain, morning stiffness for longer
than 60 minutes, maximal pain on morning)
- Contraindication to pamidronate (hypocalcaemia, severe kidney
failure or allergy)
- Underage patients, patients subject to legal protections
- Previous treatment with bisphosphonates
- Pregnancy- Daily pain for at least three months
- VAS for pain > 40/100 in the last 48 hours - Local or general infection
- Previous disc surgery- Lack of efficacy, intolerance, or contraindication to NSAIDs
- Systemic corticosteroid therapy in the last month
- Lack of efficacy of a rigid or semi-rigid back brace - Epidural or facet joint corticosteroid injection in the last month
- Modic 1 disc disease (diagnosed on MRI and confirmed by a
trained radiologist)
- History of septic spondylodiscitis
- Dental check-up within the last six months - Ankylosing spondylitis
- Low back pain associated with radiculalgia
- Signed informed consent form - Active psychiatric disorder
- Inability to read or understand French
- Body temperature greater than 38°C (fever) or erythrocyte sedimentation
rate greater than 20 mm/hour
MRI, magnetic resonance imaging; NSAIDs, non-steroidal anti-inflammatory drugs; VAS, Visual Analogic Scale.
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trial; this stratified randomization by sex and age (18 to
40 years, 40 to 50 years, and 50 to 60 years) will be car-
ried out to balance the group sizes using a computer-
generated allocation sequence with a block size of four;
this will make it possible to monitor the eligibility of pa-
tients and transfer information on the randomization to
the investigator, and possibly other correspondents.
Description of the intervention
The study product is a 10 ml vial of disodium pamidro-
nate 9 mg/ml, in a concentrated solution to be diluted in
500 ml of 0.9% sodium chloride solution, for slow intra-
venous infusion. It will be administered at the dose of
90 mg per day, for two days consecutively (for a total dose
of 180 mg), as a slow intravenous infusion as in our pilot
study [36]. We chose this administration pattern following
Sayag-Boukris et al. [27] and Solau-Gervais et al.’s [31]
method of treatment in SAPHO syndrome (60 mg each
day, for three days consecutively), but divided the total
dose of 180 mg between two days. We estimated that this
would reduce the length of stay, and knew from our pilot
study that 90 mg a day is usually well tolerated.
In the placebo group, the product used is a 500 ml bag
of 0.9% sodium chloride solution.
In case of therapeutic failure at three months, the
brace offered to patients will be a rigid or semi-rigid,
lumbar or dorsolumbar brace custom made by the Phys-
ical Medicine and Rehabilitation Department.
Outcome measures
The primary outcome measure will be the difference be-
tween D0 and D90 [16,20,22] in spinal pain assessed by
VAS [36] between the treatment group and the placebo
group (with a standard deviation of pain variation
assessed by VAS set at 30 [19,36].
The secondary outcome measures will be the differ-
ences at three months between the treatment group and
the placebo group in: the French adaptation of the
Roland-Morris Low Back Pain Questionnaire (EIFEL),
Dallas and Fear Avoidance Beliefs Questionnaire (FABQ)
scores, the McMaster Toronto Arthritis Patient Prefer-
ence Disability Questionnaire (MacTar) and the Minimum
Clinically Important Improvement/Patient Acceptable
Symptom State (MCII/PASS) questionnaire [37-40]; mea-
surements of finger-to-floor distance and the Schober test;
clinical signs of spinal inflammation, with assessment of
the number of nighttime awakenings and the duration
and severity of morning stiffness on a VAS; and safety,
with the number and severity of side effects, physical or
biological, such as hypocalcemia or renal toxicity by dos-
ages of serum calcium and creatinine.
Outcomes will also be measured at six weeks as an in-
terim evaluation, and at six months as follow up. Table 2
summarizes the data-collection schedule.
Statistical considerations
Sample size estimation
As the objective of this study is to show the efficacy of
treatment with pamidronate on spinal pain attributed to
Modic inflammatory disc disease, the justification of
sample size estimation was based on the comparison of
pain variation at three months, assessed using a VAS in
the two randomization groups.
Therefore, considering type I and type II errors of 5%
(two-sided) and 10%, respectively, 22 patients per group
are needed to demonstrate a minimum difference of 30
points on the VAS scale of 0 to 100. As some subjects
Table 2 Outcome measures at baseline, interim
assessment, three months and follow-up
Baseline Interim
assessment -
six weeks
Three
months
Follow up -
six months
Informed consent X
Inclusion and exclusion
criteria
X
Demographic data X
Medical and surgical
history
X
Adverse effects X X X
Current daily treatment X X X X
Dental status X X X X
Routine dental visit X
Physical examination X X X X
Blood test (CBC,
hs-CRP, serum calcium,
serum creatinine, ESR,
vitamin D, PTH, CTX,
osteocalcin)
X X X X
Pain on 100 mm VAS X X X X
EIFEL score X X X X
FABQ score X X X X
Dallas score X X X X
MacTar score X X X X
MCII/PASS score X X X
Finger-to-floor distance X X X X
Schober’s test X X X X
Number of nightly
awakenings
X X X X
Severity of MS
(100 mm VAS)
X X X X
Duration of MS (min) X X X X
CBC, complete blood count; CTX, C-terminal telopeptide; EIFEL: French adaptation
of the Roland-Morris Low Back Pain Questionnaire; ESR: erythrocyte sedimentation
rate; FABQ: Fear Avoidance Beliefs Questionnaire; hs-CRP: high-sensitivity
C-reactive protein; MacTar: McMaster Toronto Arthritis Patient Preference
Disability Questionnaire; MCII/PASS: Minimum Clinically Important Improvement/
Patient Acceptable Symptom State; MS: morning stiffness; PTH: parathyroid
hormone: VAS: visual analogue scale.
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may be lost to follow up, 24 patients per group will be
included.
Statistical analysis
Intention-to-treat analysis will be conducted; all statis-
tical tests will be considered for a type I error α of 5%.
Continuous variables will be presented as means and
standard deviations, provided that their distribution is
normal (Shapiro–Wilk test if needed [41]), or as me-
dians, quartiles and extrema. Categorical parameters will
be expressed as the number of subjects and associated
percentages.
The patients will be described and compared between
groups at inclusion using the following variables: fulfil-
ment of eligibility criteria, epidemiological and clinical
characteristics, and previous treatments.
As the primary outcome is variation in pain scored by
the VAS, the randomization groups will be compared
using a Student’s t-test or Mann–Whitney test if appro-
priate. Homoscedasticity will be tested using the Fisher–
Snedecor test.
The between-group comparisons at 1.5, 3 and
6 months for the other outcome measures will be con-
sidered using standard tests, as has been described for
the primary outcome measure of quantitative variables
(notably EIFEL, Dallas, FABQ, finger-to-floor distance
and Schober’s test), the Chi2 test or, where applicable,
Fisher’s exact test for the qualitative variables. These
between-group comparisons will be made systematically
without adjustment, and by adjusting for factors whose
distribution could be imbalanced between groups despite
the randomization or due to clinical relevance (including
analgesic use, treatments (and modifications) and other
co-interventions during the study, such as physiother-
apy). To measure the changes in the variables collected
over the different visit time-points, a longitudinal data
analysis will be conducted via ANOVA (ANalysis Of
Variance) for repeated measures or the Friedman test (if
ANOVA conditions are not fulfilled), followed by a
post-hoc test and mixed models to take into account
within- and between-patient variability. The intragroup
comparisons, conducted secondarily, will be imple-
mented via paired Student’s t-test or Wilcoxon test for
the quantitative variables, and the Stuart–Maxwell test
for the qualitative variables. Due to multiple compari-
sons envisaged at these three time-point evaluations, the
inflation of type I error will be taken into account for
each additional endpoint (Bonferroni adjustment should
not be too conservative with only three time-points).
The rate of subjects lost to follow up at three months is
considered to be minor; the inclusion of 24 subjects is
planned, while 22 patients should be necessary. In order
to assess the problem caused by missing longitudinal
data, estimation methods developed by Verbeke and
Molenberghs [42] will be considered. For other missing
data, if the frequency of missing data is >5%, an add-
itional analysis will be performed using the multiple im-
putation method (Stata’s mi command software [43]).
Discussion
The treatment options for Modic type 1 disc diseases re-
main quite limited; invasive local treatments, such as
intradiscal injections of cortisone derivatives or spinal
arthrodesis, have generated controversial results [21,22],
and the brace remains a last-resort solution for patients
who wish to maintain some mobility and often consider
it cumbersome and unsightly.
There are, to date, no published controlled trials in-
volving pamidronate in EDDD. The results from our
pilot study (an open-label study with ten subjects) were
encouraging [36], and therefore we hypothesized, in light
of this pilot study and the widespread use of pamidro-
nate in painful bone diseases, that pamidronate could be
effective in relieving EDDD-induced pain. However, the
efficacy of pamidronate in this condition clearly required
further investigation in a prospective, blinded, random-
ized controlled trial. Subject recruitment began in Janu-
ary 2013 and will continue until the end of December
2014, with the results made available in March 2015.
Regarding safety concerns, vitamin D blood levels will
be measured before the product is administered and pa-
tients will be given vitamin D supplementation accord-
ingly prior to treatment [44]. Every patient will also be
examined by the dentist affiliated with the study to look
for, and if necessary treat, contraindications to intraven-
ous bisphosphonates.
All studies include biases, and we have taken several
steps to limit those that could arise in this study; as
pamidronate can cause fever and flu-like syndromes, the
patient will be included by one physician and evaluated
by another. In addition, to minimize this effect, patients
from both groups will receive 1 g of paracetamol prior
to the infusion and 1 g of paracetamol every 8 hours for
48 hours. To guarantee the double-blind and prevent
biases in monitoring and measurement, physicians from
the Rheumatology Department will be responsible for
administering the product and monitoring the side ef-
fects (such as hyperthermia in cases of patients receiving
pamidronate despite the administration of paracetamol,
which would result in unblinding for both the patient
and physician), and physicians, physiotherapists and oc-
cupational therapists from the Physical Medicine and
Rehabilitation Department will be responsible for assess-
ments (D0, D45, D90 and D180). In addition, and again
to guarantee the blinding for the patient, the products
administered intravenously will be identified not by the
product name but by the patient’s randomization num-
ber, and will be prepared by the hospital pharmacy so
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that the nurses performing the infusions will not know
which product is infused to the patient. Treatment
changes over the six months of follow up will be re-
corded and, to prevent a recall bias, each patient will be
given a diary including a table to be completed following
each change in his or her standard treatment. Finally, an
experienced radiologist affiliated with the study and spe-
cializing in osteoarticular diseases is responsible for con-
firming each radiological diagnosis of Modic type 1 disc
disease on an MRI scan. Concerning the sample size es-
timation, the assumption of our protocol is that the
standard-deviation of the difference (test versus control)
in change scores (initial versus final) is the same as the
previous standard-deviation of the change score found
for treated patients in the open pilot study [36]. There-
fore, sample size estimation is based on previous works,
which could be considered heterogeneous for the
standard-deviation of the change score. In our pilot
study [36], the standard-deviation of VAS was 19.1 at
baseline, 22.7 at three months and 24.1 for change score.
As standard-deviation equals 30, our estimation appears
near to the expected results and overestimates the value
obtained in the pilot study. Nevertheless, blinded studies
have a smaller effect which may not be captured by the
standard-deviation. Moreover, the statistical power was
voluntarily more important than 80% (1-β fixed equals
90%). Concerning the statistical approach, the primary
outcome analysis will be pain-VAS difference at three
months using a Student’s t-test if normally distributed
and a Mann–Whitney test if not. In the secondary out-
come analysis, a multivariate situation should be proposed
using a linear regression model to take adjustment factors
into account. Adjustments may threaten the randomized
nature of the study. To further ensure the randomization
of the study, a random-effect model, considering block as
a random effect could be proposed.
Trial status
PEPTIDE is ongoing and currently recruiting.
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